In contrast, ibrutinib but not acalabrutinib impairs FcγR-mediated ADCP of opsonized CLL cells by human macrophages likely via off-target inhibition of TEC (Figure 1 and Table 2), suggesting differential potential of these two BTK inhibitors in combination therapies with various depleting antibodies. Here, FCGR2A is linked to B-cell chronic lymphocytic leukemia.